Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

3 clinical studies listed.

Filters:

Vascular Aging

Tundra lists 3 Vascular Aging clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

NOT YET RECRUITING

NCT07328100

Efficacy and Safety of Coenzyme I for Injection on Vascular Aging.

Emerging evidence identifies vascular aging independently predicting cardiovascular events, yet effective clinical interventions remain lacking. Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor whose levels decline with age, and preclinical studies suggest that boosting NAD+ can improve vascular function and structure. Preliminary clinical studies in healthy older adults indicate that supplementation with NAD+ precursors, such as nicotinamide riboside(NR) or nicotinamide mononucleotide (NMN), can reduce arterial stiffness as measured by pulse wave velocity (PWV). However, whether NAD+ supplementation can improve vascular endothelial function and exert anti-stiffening effects in patients who have already developed measurable arterial stiffness remains unknown. Based on this evidence, the investigator hypothesize that the Coenzyme I for Injection will reverse vascular aging in older adults with established arterial stiffening.

Gender: All

Ages: 40 Years - 70 Years

Updated: 2026-01-08

1 state

Vascular Aging
NAD
RECRUITING

NCT04413994

Exclusive Human-milk in Preterm NEOnates and Early VASCular Aging Risk Factors (NEOVASC)

Early vascular aging has its origins in fetal and neonatal life. The NEOVASC clinical trial aims to determine the effects of an exclusive human milk diet in extremely preterm infants on long-term cardiovascular health.

Gender: All

Ages: 1 Day - 5 Years

Updated: 2025-08-29

1 state

Prematurity
Vascular Aging
ACTIVE NOT RECRUITING

NCT05296395

Vascular Aging and Lp299v Study

Emerging data suggest the gut microbiota regulates multiple mechanisms related to vascular aging, but no intervention targeting the gut microbiota has been tested in older adults without cardiovascular risk factors or cardiovascular disease. Early human data suggest an increase in potentially pathological gut metabolites such as trimethylamine-N-oxide (TMAO) are associated with older age, increased vascular stiffness, increased oxidative stress, and reduced nitric oxide (NO) bioavailability as evidenced by impaired endothelium-dependent vasodilation. Based on this data, the investigators hypothesize that supplementation with Lp299v will reverse human vascular aging in healthy older adults free of known traditional cardiovascular risk factors.

Gender: All

Ages: 50 Years - 99 Years

Updated: 2025-04-27

1 state

Vascular Aging